MGF Protocol: Complete Cycling & Dosing Guide

MGF Protocol: Complete Cycling & Dosing Guide

Overview

Mechano Growth Factor (MGF) is a splice variant of IGF-1 produced locally in muscle tissue following mechanical stress and exercise-induced damage. Unlike systemic IGF-1, MGF acts locally at injection sites to activate satellite cells, promote myoblast proliferation, and accelerate muscle repair and hypertrophy. Understanding proper cycling, dosing, and administration is critical for safety and efficacy.

MGF is administered via intramuscular injection directly into target muscles. The standard dosing range is 100-200 mcg per administration, 2-3 times weekly. Most protocols use a 12-16 week cycle followed by an off-period, though shorter 8-week cycles and extended 20-week protocols exist depending on goals and individual response.

Key distinctions from IGF-1:

• Local action at injection site rather than systemic distribution
• Activates satellite cells through distinct signaling pathways (PI3K/Akt and MAPK/ERK)
• Lower systemic hypoglycemia risk but still possible
• Can produce asymmetric muscle growth if used site-specifically (an advantage or disadvantage depending on intent)

Standard Protocol

Baseline Dosing Structure

Conservative Approach (Lower Risk):

• Dose: 100 mcg per injection
• Frequency: 2 times per week
• Total weekly: 200 mcg
• Cycle length: 12 weeks on, 4 weeks off
• Injection sites: Rotate between major muscle groups (quads, chest, shoulders, glutes)

Standard Approach (Moderate):

• Dose: 150 mcg per injection
• Frequency: 2-3 times per week
• Total weekly: 300-450 mcg
• Cycle length: 14 weeks on, 4-6 weeks off
• Injection sites: Target muscles aligned with training focus

Advanced Approach (Higher Dose):

• Dose: 200 mcg per injection
• Frequency: 3 times per week
• Total weekly: 600 mcg
• Cycle length: 16 weeks on, 6 weeks off
• Injection sites: Site-specific targeting for lagging muscle groups

Dose Escalation Protocol (Recommended for New Users)

Week 1-2: 100 mcg × 1 injection per week (assess tolerance) Week 3-4: 100 mcg × 2 injections per week Week 5-6: 150 mcg × 2 injections per week Week 7+: 150-200 mcg × 2-3 injections per week (based on response)

This gradual approach identifies individual sensitivity to injection site effects and systemic responses before committing to higher volumes.

Goal-Specific Protocols

Protocol A: Muscle Hypertrophy (Primary Goal)

Duration: 16 weeks on, 6 weeks off

Dosing:

• Weeks 1-6: 100 mcg × 2 per week (200 mcg/week total)
• Weeks 7-12: 150 mcg × 3 per week (450 mcg/week total)
• Weeks 13-16: 150-200 mcg × 3 per week (450-600 mcg/week total)
• Weeks 17-22: Off

Injection Timing: Inject immediately post-workout into the trained muscle group when possible. MGF peaks in muscle 6-24 hours post-mechanical stress, so timing injections within 2-4 hours of training maximizes satellite cell activation.

Adjuncts: Pair with high-volume resistance training (10-20 sets per muscle group per week), adequate protein intake (0.8-1g per lb body weight), and caloric surplus if building mass is priority.

Expected Timeline: Measurable hypertrophy typically appears by Week 4-6; accelerated growth by Week 10-14.

Protocol B: Injury Recovery & Connective Tissue Repair

Duration: 8-12 weeks on, 2-4 weeks off (cycling based on recovery timeline)

Dosing:

• 150 mcg injected directly into the injured or recovering tissue
• Frequency: 2 times per week for 8 weeks
• Then evaluate tissue response before cycling off

Injection Technique: Administer as close to the injury site as safely possible (e.g., into the muscle adjacent to a tendon injury, or surrounding the damaged tissue). This maximizes local MGF concentration at the repair site.

Adjuncts: Combine with appropriate physical therapy, immobilization during acute phase if indicated, and gradual loading once acute inflammation resolves.

Expected Timeline: Pain reduction and functional improvement typically visible by Week 2-3; structural repair progresses over Weeks 4-12.

Protocol C: Joint Health & Cartilage Protection

Duration: 12-14 weeks on, 4 weeks off

Dosing:

• 100-150 mcg × 2 per week
• Inject into muscles surrounding the affected joint (e.g., vastus medialis and lateralis for knee OA; posterior deltoid and infraspinatus for shoulder)
• Total weekly: 200-300 mcg

Rationale: Direct injection into cartilage is not safe; instead, stimulate local muscle tissue surrounding the joint to promote anti-inflammatory cytokine production (IL-10) and reduce TNF-α and IL-17 expression through muscle-derived signaling.

Adjuncts: Combine with resistance training targeting stabilizer muscles, joint mobility work, and potentially oral collagen or hyaluronic acid supplementation.

Protocol D: Off-Season or Deload Maintenance

Duration: Continuous low-dose maintenance, 8-12 weeks on, 2 weeks off

Dosing:

• 100 mcg × 2 per week (200 mcg/week total)
• Lower volume and intensity training
• Inject into all major muscle groups on a rotating basis

Rationale: Maintains satellite cell responsiveness and muscle protein synthesis during lower training phases without the accumulative stress of higher doses.

How to Administer: Step-by-Step

Reconstitution (if lyophilized powder)

1. Prepare sterile workspace: Clean vial tops and injection surfaces with alcohol swabs.
2. Draw bacteriostatic water: Use a sterile syringe and 23g needle; typical reconstitution is 100 mcg per 0.5 mL water (200 mcg/mL concentration) or 100 mcg per 1 mL (100 mcg/mL).
3. Inject water into MGF vial: Slowly inject the reconstitution fluid into the powder vial. Do not shake vigorously; gently roll the vial between your palms until fully dissolved. Some particulates may remain; this is normal.
4. Verify clarity: Reconstituted MGF should be clear to slightly opalescent. Discard if cloudy or discolored.
5. Mark reconstitution date: Use a sterile marker to label the vial with the date and time.
6. Storage: Refrigerate at 2-8°C (35-46°F) after reconstitution. Reconstituted MGF is stable for approximately 14-21 days under proper refrigeration.

Injection Technique

1. Select injection site: Choose a major muscle group (quadriceps, gluteus maximus, chest, shoulders, or lateral deltoid). Rotate sites every injection to prevent repeated tissue trauma and lipohypertrophy.

2. Prepare the site: Clean a 2-3 inch area of skin with an alcohol swab using a circular motion, starting from the center and moving outward. Allow alcohol to air dry (15-20 seconds).

3. Draw dose: Use a sterile 0.5-1 mL insulin syringe (31-32g needle) or a 3 mL syringe with 25-27g needle. Draw the calculated dose based on your reconstitution concentration (e.g., if 200 mcg/mL and you want 150 mcg, draw 0.75 mL).

4. Insert needle: Pinch the skin at the injection site to create a raised area. Insert the needle at a 90-degree angle, perpendicular to the skin surface. Penetrate approximately 1-1.5 inches into the muscle belly.

5. Aspirate: Gently pull the plunger back slightly to confirm you are not in a blood vessel (no blood should appear in the syringe). If blood appears, withdraw and select a new site.

6. Inject slowly: Depress the plunger steadily over 5-10 seconds to distribute the peptide throughout the muscle tissue.

7. Withdraw: Remove the needle at the same 90-degree angle. Do not rub the injection site; light pressure with a clean gauze pad for 10-15 seconds is sufficient.

8. Dispose safely: Place the used syringe and needle into a sharps container. Do not reuse needles or syringes.

Timing Relative to Training

Optimal timing: Inject into the target muscle 1-4 hours post-workout when mechanical stress has already stimulated local MGF mRNA upregulation. This "stacks" the endogenous exercise response with exogenous MGF peptide.

Alternative: If not training that day, inject at a consistent time (e.g., every Monday and Thursday morning) to maintain steady local peptide levels.

Cycle Example: 16-Week Hypertrophy Cycle (Week-by-Week)

Post-Cycle: Weeks 17-22 allow satellite cells to fully differentiate into mature muscle fibers and prevent receptor downregulation from continuous stimulation.

What to Expect: Timeline of Effects

Week 1-3 (Honeymoon Phase):

• Increased muscle fullness and pump during training
• Enhanced recovery (reduced soreness by 30-50%)
• Possible injection site soreness, mild redness, or swelling (transient)
• Minimal changes in muscle mass; primarily neuromuscular adaptation

Week 4-6 (Early Growth Phase):

• Noticeable increase in strength on compound lifts (+5-15%)
• Muscle measurements increase (primarily myonuclei accumulation; not yet substantial hypertrophy)
• Recovery continues to improve
• Training volume tolerance increases
• Injection site effects typically resolve

Week 7-10 (Acceleration Phase):

• Visible hypertrophy emerges (+0.5-1.5 inches on major muscle groups)
• Strength gains accelerate (+10-25%)
• "Flatness" or loss of vascularity if in caloric deficit (MGF shifts nutrients toward muscle repair, away from cosmetic conditioning)
• Some users report lethargy or fatigue at higher doses; manage with sleep and nutrition

Week 11-14 (Peak Growth Phase):

• Most dramatic hypertrophy gains occur
• +1-3 inches possible on chest, arms, or quads (highly dependent on training and diet)
• Asymmetric growth becomes apparent if injecting single muscle groups repeatedly
• Strength plateaus or slows if not adjusting training stimulus

Week 15-16 (Plateau & Taper):

• Growth rate declines (receptor saturation, reduced stimulus novelty)
• Strength may decline slightly if reducing injection frequency
• Energy and recovery remain enhanced

Week 17-22 (Off-Cycle Recovery):

• Satellite cells differentiate into mature muscle fiber nuclei; gains solidify
• Some transient strength and fullness loss (expected 5-10%)
• Receptor sensitivity resets; hypoglycemia risk disappears
• Fatigue/lethargy resolves

Common Protocol Mistakes

Mistake 1: Incorrect Injection Depth Injecting subcutaneously rather than intramuscularly dramatically reduces efficacy (MGF is meant for local muscle action). Ensure needle penetrates 1-1.5 inches into the muscle belly.

Mistake 2: Not Rotating Injection Sites Repeated injections into identical muscle areas cause localized inflammation, scar tissue formation, and lipohypertrophy (muscle death and fat replacement). Rotate sites every 1-2 injections.

Mistake 3: Injecting Without Training Stimulus MGF amplifies the satellite cell activation triggered by mechanical stress. Using MGF during a deload or rest week is inefficient. Coordinate injections with resistance training.

Mistake 4: Using Excessive Doses Too Early Starting at 200 mcg × 3/week causes unnecessary injection site pain and increases hypoglycemia risk without proportional benefit. Escalate gradually over 4-6 weeks.

Mistake 5: Insufficient Caloric or Protein Intake MGF activates satellite cells and protein synthesis, but without adequate amino acids and calories, hypertrophy won't manifest. Target 0.8-1.0 g protein per lb of body weight and +300-500 kcal above maintenance.

Mistake 6: Continuing High Doses Beyond 16 Weeks Extended cycles beyond 16 weeks without a break risk receptor downregulation, compounded injection site stress, and potential receptor mutation. Always include a 4-6 week off-cycle.

Mistake 7: Injecting Into Injured or Acutely Inflamed Tissue During the acute inflammation phase of injury, exogenous MGF may exacerbate swelling. Wait until acute phase resolves (3-7 days) before injecting into or adjacent to injury sites.

How to Stack with Other Compounds

MGF + Resistance Training Alone

Gold standard for natural or conservative users. MGF amplifies the endogenous growth factor response; no pharmacological stacking required. Optimal results with high-volume training (12-20 sets per muscle group per week), caloric surplus, and 0.8-1.2 g protein per lb.

MGF + IGF-1 (Systemic)

Complementary but requires careful dosing. Inject MGF locally into target muscles; run systemic IGF-1 at moderate doses (40-80 mcg per day) subcutaneously. MGF provides localized satellite cell activation; IGF-1 provides systemic protein synthesis and recovery. Risk: Compounded hypoglycemia. Monitor blood glucose weekly. Cycle: 12 weeks on both, 4 weeks off both.

MGF + Growth Hormone

Synergistic and evidence-supported. Growth hormone stimulates endogenous IGF-1 production and enhances recovery; MGF amplifies local myoblast proliferation. GH dose: 2-4 IU daily (subcutaneous); MGF: 150 mcg × 2-3 weekly (intramuscular). Cycle: 16 weeks on both, 4-6 weeks off. Research shows 456% MGF mRNA upregulation with combined GH + resistance training vs. 163% with training alone.

MGF + Testosterone (Exogenous)

Powerful for muscle building; requires monitoring. Testosterone increases satellite cell number and androgen receptor expression; MGF activates satellite cells locally. Combined result: Accelerated hypertrophy. Testosterone dose: 300-600 mg weekly (per standard protocols); MGF: 150-200 mcg × 3 weekly. Cycle: 12-16 weeks on both, 6 weeks off. Requires estrogen management (AI if needed) and cardiov